Jump to content

Mike

Members
  • Posts

    23
  • Joined

  • Last visited

Everything posted by Mike

  1. Doctors probably have two week trial packs and there is this thing called insurance...
  2. Primavanserin does seem like an obvious no brainer concerning HPPD/VSS. Probably a lower dosage over, I don't know, six months or something. Sort of surprising nobody has gone there.
  3. Here's a link to part of that guys book(post lsd syndrome) if your interested https://books.google.com/books?id=KKYh00o69TUC&pg=PA58&lpg=PA58&dq=thiothixene+lsd&source=bl&ots=TzolEssc07&sig=q6EOTJuaH09Ok7CWdScOWTQn3co&hl=en&sa=X&ved=0ahUKEwiA3_PN8rTUAhWG6iYKHbeIDKYQ6AEIRTAD#v=onepage&q=thiothixene lsd&f=false
  4. http://www.blogtalkradio.com/powerful-patient/2012/04/13/curing-the-post-lsd-syndrome Ketaserin is an older hypertensive agent, also sold as a gel that is related to Nuplazid(primavanserin). It seems to come up a lot when researching this area. It seems like researchers are aware of its LSD blocking capabilities and effects on seretonin, however, it's only I guess shown to stop the effects of lsd when taken prior to ingestion??? Though I have never heard of anybody using it for this condition before this article was recently published. Not sure about availability. https://www.theverge.com/2017/1/26/14388034/lsd-acid-neuroscience-trip-meaning-research-science
  5. Dr Kremens: NUPLAZID is a selective serotonin inverse agonist. To understand this, you have to understand how receptors in the brain work. Many receptors in the brain are capable of initiating signals even when they are not being stimulated, even when you don’t have an agonist bound to that receptor. Signaling can occur without an agonist; that is called basal activity. If you have an agonist, that stimulates a receptor and increases the activity of that receptor. Then there are drugs called antagonists. Antagonists block the agonist, but they permit the ongoing basal activity. Then you have inverse agonists. Inverse agonists suppress basal activity. So, with NUPLAZID, you are suppressing the basal activity of some serotonin receptors in the brain. It’s thought that the effect of NUPLAZID is a result of a combination of an inverse agonist and antagonist activity at serotonin receptors.- See more at: http://www.ajmc.com/journals/supplement/2016/understanding-the-burden-and-management-of-hallucinations/a645-article/P-4#sthash.O13qeyGg.dpuf so even if your antagonizing the receptor your still activating it in a sense, antagonism returns it to it "baseline". But if it's stuck being hyperactive so to speak, inverse agonism depresses it, it's different, a lower baseline. The "volume" is what needs to be lowered.
  6. Dr Kremens: NUPLAZID is a selective serotonin inverse agonist. To understand this, you have to understand how receptors in the brain work. Many receptors in the brain are capable of initiating signals even when they are not being stimulated, even when you don’t have an agonist bound to that receptor. Signaling can occur without an agonist; that is called basal activity. If you have an agonist, that stimulates a receptor and increases the activity of that receptor. Then there are drugs called antagonists. Antagonists block the agonist, but they permit the ongoing basal activity. Then you have inverse agonists. Inverse agonists suppress basal activity. So, with NUPLAZID, you are suppressing the basal activity of some serotonin receptors in the brain. It’s thought that the effect of NUPLAZID is a result of a combination of an inverse agonist and antagonist activity at serotonin receptors.- See more at: http://www.ajmc.com/journals/supplement/2016/understanding-the-burden-and-management-of-hallucinations/a645-article/P-4#sthash.O13qeyGg.dpuf
  7. This is a related drug "in the model of" the drug mentioned above that has not made it through the drug approval pipeline yet, probably a couple more years if not fast tracked. I bring it up because the chart on this website kind of simply explains the mechanism of this new class. It is literally described as .... "The candidate, nelotanserin, targets the 5HT2A receptor for serotonin in cells from the central nervous system. Its activation is the basis of psychedelic drugs such as LSD. Nelotanserin does the opposite, blocking its activity to reduce hallucinations in patients with DLB and PDD." http://labiotech.eu/axovant-sciences-bermuda-dementia/
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.